CNTX Historical PE Ratio Notes

— Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for solid tumors, with particular emphasis on hormone-driven cancers such as breast, ovarian, and endometrial cancers. The company's lead candidate, onapristone extended release (ONA-XR), is a novel oral progesterone receptor antagonist designed to target key mechanisms driving tumor growth. CNTX operates in the high-risk, high-reward realm of drug development, often characterized by significant research & development expenses and, typically, a lack of positive earnings until late in the clinical pipeline or after product approvals. As a result, the historical price-to-earnings (PE) ratio for CNTX—when even calculable—may be extremely high or not meaningful (e.g., ȁcN/Aȁd if earnings are negative), which is common for early-stage biotech companies. When reviewing CNTX's historical price, earnings, and PE ratio data, keep in mind that traditional valuation metrics like the PE ratio often don't capture the forward-looking, milestone-driven nature of biotechs. Market sentiment, clinical trial progress, & news about regulatory developments often have a greater impact on CNTX's valuation than earnings themselves.

On this page we presented the CNTX Historical PE Ratio information for Context Therapeutics' stock. The average CNTX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CNTX historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CNTX historical PE result, against the recent PE: when this page was posted on 3/27/2026, the most recent closing price for CNTX had been 2.59, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CNTX or any other given stock, valuation analysis for CNTX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Context Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CNTX. Thanks for visiting, and the next time you need to research CNTX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.